Biography

Brian Stuglik, RPh

Mr Stuglik served as the Chief Executive Officer (CEO) of Verastem Oncology from 2019 through 2023. Mr Stuglik is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in US and international pharmaceutical development, product strategy, commercialization, and business development. He spent the majority of his career at Eli Lilly and Company, culminating in his role as Global Vice President and Chief Marketing Officer, Oncology Global Marketing, advancing Lilly Oncology from a single approved product to a portfolio of marketed or late-stage compounds across more than 10 cancer types. He was a founding member of Proventus Health Solutions, assisting biotech companies integrate development and commercial considerations into a unified approach. He is a member of the Board of Directors for Verastem Oncology (VSTM), Oncopeptides AB (ONCO), and Puma Biotechnologies, Inc (PBYI). Mr Stuglik earned his Bachelor of Science in pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.

Investor Contact

getty
Dan Calkins

Investor Relations
781-469-1694
dcalkins@verastem.com

Ryan Porter

Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com